210 related articles for article (PubMed ID: 36363465)
1. The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy.
Halalsheh OM; Al Zu'bi YO; Al Sharie AH; Wafai FH; Alabdallah N; AlSeidi J; Hussein AA; Daoud MN; Malkawi AA; Alomari AO; Alshari O
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363465
[No Abstract] [Full Text] [Related]
2. Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor.
Alshari O; Al Zu'bi YO; Al Sharie AH; Wafai FH; Aleshawi AJ; Atawneh FH; Obeidat HA; Daoud MN; Khrais MZ; Albals D; Tubaishat F
Ther Clin Risk Manag; 2021; 17():963-973. PubMed ID: 34522100
[TBL] [Abstract][Full Text] [Related]
3. Platelet-lymphocyte Ratio After Granulocyte Colony Stimulating Factor Administration: an Early Prognostic Marker in Septic Shock Patients With Chemotherapy-Induced Febrile Neutropenia.
Kim YJ; Kang J; Ryoo SM; Ahn S; Huh JW; Kim WY
Shock; 2019 Aug; 52(2):160-165. PubMed ID: 30148761
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
Singh AD; Parmar S; Patel K; Shah S; Shore T; Gergis U; Mayer S; Phillips A; Hsu JM; Niesvizky R; Mark TM; Pearse R; Rossi A; van Besien K
Biol Blood Marrow Transplant; 2018 Feb; 24(2):288-293. PubMed ID: 29061534
[TBL] [Abstract][Full Text] [Related]
5. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study.
Tian W; Wang Y; Zhou Y; Yao Y; Deng Y
Front Oncol; 2022; 12():777602. PubMed ID: 35547875
[TBL] [Abstract][Full Text] [Related]
6. Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital.
Osmani AH; Ansari TZ; Masood N; Ahmed B
Asian Pac J Cancer Prev; 2012; 13(6):2523-6. PubMed ID: 22938399
[TBL] [Abstract][Full Text] [Related]
7. Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.
Chiarotto JA; Dranitsaris G
Support Care Cancer; 2013 Oct; 21(10):2727-31. PubMed ID: 23708859
[TBL] [Abstract][Full Text] [Related]
8. Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
Kang KW; Kim DS; Lee SR; Sung HJ; Kim SJ; Choi CW; Kim BS; Park Y
Leuk Res; 2017 Jun; 57():1-8. PubMed ID: 28231491
[TBL] [Abstract][Full Text] [Related]
9. Colony-stimulating factors for chemotherapy-induced febrile neutropenia.
Mhaskar R; Clark OA; Lyman G; Engel Ayer Botrel T; Morganti Paladini L; Djulbegovic B
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD003039. PubMed ID: 25356786
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
13. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
14. Navigating the neutropenic abyss with granulocyte transfusions: Retrospective single-center analysis of effectiveness and safety in India.
Desai P; Navkudkar A; Bagal B; Dhamne C; Jain H; Sengar M; Chinnaswamy G; Nayak L
J Clin Apher; 2023 Dec; 38(6):703-710. PubMed ID: 37560907
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study.
Geissler K; Koller E; Hubmann E; Niederwieser D; Hinterberger W; Geissler D; Kyrle P; Knöbl P; Pabinger I; Thalhammer R; Schwarzinger I; Mannhalter C; Jaeger U; Heinz R; Linkesch W; Lechner K
Blood; 1997 Jul; 90(2):590-6. PubMed ID: 9226158
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
20. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol.
Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
